INTRODUCTION
Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control.
METHODS
This multicenter retrospective analysis of prospectively collected LANDSC...
L. Potestio, M. Bianco, L. Mastorino et al.· Dermatologic Therapy· 0 citations
Atopic dermatitis (AD) is a chronic inflammatory skin disorder modulated by complex interactions between immune dysregulation and compromised skin-barrier integrity, in which the gut microbiome may play a role in the natural course of the disease. Therefore, by influencing the composition of the gut microbiome, one of...
M. Salvatore, Angela Maione, E. D. Di Brizzi et al.· Journal of Pharmaceutical an...· 0 citations
Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 weeks in routine...
L. Potestio, S. Corrao, L. Mastorino et al.· Dermatologic Therapy· 0 citations
Evaluated postbiotic preparations derived from the probiotic yeast Pichia kudriavzevii isolated from a homemade kefir highlight the potential of P. kudriavzevii-derived postbiotics as multifunctional agents capable of controlling biofilm-associated infections, modulating inflammation, and supporting tissue repair.
Angela Maione, Annalisa Buonanno, Lea Di Massa et al.· Frontiers in Microbiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.